PVCT Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company. It engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treats several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A. Wachter in 2002 and is headquartered in Knoxville, TN.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.07    OTCQB
As of 01/24/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  06/07/2000
Outstanding shares:  419,447,119
Average volume:  322,949
Market cap:   $28,899,906
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   -1.28
PS ratio:   0.00
Return on equity:   202.54%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy